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cDepartment of Radiology, St Elizabeth’s Medical Center, Affiliate of Tufts University School of Medicine, Boston, Massachusetts, USAAbstractObjective: Benign breast masses, such as fibroadenomas, are common, and their management is variable, depending on symptoms and
patient concerns. We undertook this study to determine the safety, efficacy, and patient acceptance of percutaneous excision of benign breast
masses by using a hand-held vacuum-assisted device.
Methods: By using sonographic guidance, percutaneous removal was performed in 40 patients with 42 lesions by using a 9-gauge (n ¼ 13) or
12-gauge (n ¼ 29) probe (ATEC; Suros Surgical). Technical success, procedural complications, and patient experience were recorded at the
time of excision and at 48 hours. Clinical, imaging, and/or surgical follow-up was obtained for 39 of 42 lesions (93%). Three of 42 lesions
(7%) were lost to follow-up.
Results: Of 42 lesions, maximal diameters ranged from 0.6e4.0 cm (mean 1.6 cm), with lesion volumes between 0.05 and 11.2 mL (mean
[SD] 1.4 ± 2.1 mL, median 7 mL). The procedure was well tolerated by all patients, and no residual mass was visible in any case at the
conclusion of the procedure. All the patients preferred this approach to open surgical biopsy. After percutaneous excision, surgery was
performed on 3 of 42 lesions (7%) for atypia (n ¼ 2) or malignancy (n ¼ 1), with a residual mass found only for the malignant case. Of the 26
of 42 lesions (62%) with imaging follow-up, 24 (92%) had no lesion recurrence. Overall, the procedure either completely removed the mass
and/or relieved the patient’s symptoms of a mass in 36 of 39 lesions (92%) for which clinical, imaging, and/or surgical follow-up was
available. Three lesions were lost to follow-up.
Conclusion: Ultrasound-guided percutaneous excision of benign breast masses is a safe, effective, and well-tolerated minimally invasive
procedure for the diagnosis and removal of benign breast masses. It may serve as an alternative to surgical excision for women with a known
benign or probably benign breast mass who desire excision but prefer to avoid surgery or who are poor surgical candidates.Re´sume´Objectif: Les tumeurs be´nignes au sein comme les fibroade´nomes sont fre´quentes et leur traitement varie selon les symptoˆmes et les
pre´occupations des patientes. Nous avons re´alise´ cette e´tude afin de de´terminer a` quel point l’excision percutane´e des tumeurs be´nignes au
sein re´alise´e au moyen d’un appareil a` pression ne´gative tenue a` la main e´tait se´curitaire, efficace et accepte´e par les patientes.
Me´thodes: A` l’aide d’un sonographe, une ablation percutane´e a e´te´ effectue´e chez 40 patientes qui pre´sentaient un total de 42 ; le´sions au
moyen d’une sonde de calibre 9 (n ¼ 13) ou de calibre 12 (n ¼ 29) de marque ATEC de Suros Surgical. On a consigne´ la re´ussite de
l’intervention, les complications chirurgicales et la tole´rance des patientes au moment de l’excision et apre`s 48 heures. Un suivi clinique,
chirurgical ou en imagerie a e´te´ effectue´ pour 39 des 42 le´sions (93 %). Trois des 42 le´sions (7 %) n’ont fait l’objet d’aucun suivi.
Re´sultats: Sur les 42 le´sions, le diame`tre maximal variait de 0,6 a` 4 cm (moyenne de 1,6 cm) et le volume, de 0,05 a` 11,2 ml (moyenne [e´cart
type] de 1,4 ± 2,1 ml, me´diane de 7 ml). Toutes les patientes ont bien tole´re´ l’intervention et, dans tous les cas, aucune tumeur re´siduelle
n’e´tait visible a` la fin de la proce´dure. Les patientes ont toutes pre´fe´re´ cette me´thode a` la biopsie chirurgicale ouverte. Apre`s l’excision
percutane´e, on a pratique´ une chirurgie pour trois des 42 le´sions (7 %) en raison d’une tumeur atypique (n ¼ 2) ou maligne (n ¼ 1) et on
a de´cele´ une masse re´siduelle uniquement dans le cas de la tumeur maligne. Sur les 26 des 42 le´sions (62 %) ayant fait l’objet d’un suivi en
imagerie, il n’y a eu aucune re´cidive dans 24 cas (92 %). Dans l’ensemble, l’intervention a permis de retirer comple`tement la tumeur ou de* Address for correspondence: Priscilla J. Slanetz, MD, MPH, FACR, Department of Radiology, Shapiro Building, 4th floor, Beth Israel Deaconess Medical
Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA.
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266 P. J. Slanetz et al. / Canadian Association of Radiologists Journal 62 (2011) 265e271soulager les symptoˆmes de la patiente pour 36 des 39 le´sions (92 %) ayant fait l’objet d’un suivi clinique, chirurgical ou en imagerie. Trois
le´sions n’ont fait l’objet d’aucun suivi.
Conclusion: L’excision percutane´e guide´e par ultrasons des tumeurs be´nignes au sein est une intervention a` effraction minimale, se´curitaire,
efficace et bien tole´re´e permettant le diagnostic et l’ablation de tumeurs be´nignes au sein. Cette technique peut servir de solution de rechange
a` l’excision chirurgicale pour les femmes connue porteuse d’une tumeur mammaire be´nigne ou probablement be´nigne et qui souhaitent subir
une excision, mais pre´fe`rent e´viter la chirurgie ou dont le cas se preˆte mal a` la chirurgie.
 2011 Canadian Association of Radiologists. All rights reserved.
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Although breast cancer will affect 1 in 8 women in their
lifetime [1], current data estimate that 60% of all adult
women will acquire some form of benign breast disease
during their lifetime. Moreover, up to 90% of clinical breast
presentations are related to benign disease rather than
malignancies [2]. Although benign breast diseases are not
life threatening, they may cause the patient emotional
distress and physical discomfort, such as pain, lump, or
discharge. Not only do these lesions cause anxiety for the
patient, but, also, these lesions may grow over time by
making their ultimate removal more difficult and less
cosmetically pleasing [2].
One of the most common lesions is the fibroadenoma.
Although this neoplasm is benign, its management is variable
and depends primarily on the presence or absence of symp-
toms, interval growth, or patient concern for contiguous
malignancy. Surgical excision remains the mainstay for some
fibroadenomas, but it carries certain risks, including subop-
timal cosmesis, which could potentially complicate inter-
pretation of subsequent mammograms [3]. In addition,
16%e20% of women with multiple symptomatic fibroade-
nomas, most of whom are under the age of 50 years, often
have to undergo many surgeries that result in multiple visible
scars.
For 2 decades, a diagnosis of fibroadenoma and other
benign breast masses has been undertaken by using image-
guided core needle biopsy. Results of multiple studies have
shown that needle biopsy is safe and accurate in the diag-
nosis of a benign breast mass and with even greater certainty
when performed with a vacuum-assisted device rather than
a spring-loaded device, because of larger sample sizes [3e
17]. With the introduction of vacuum-assisted devices, it
now is technically possible to percutaneously excise a mass.
Although these devices are not approved by the U.S. Food
and Drug Administration for percutaneous excision, many
women seek less-invasive treatments for symptomatic benign
or probably benign diagnoses in hopes of symptomatic relief
and improved cosmesis.
Several studies used 1 of the early vacuum-assisted
devices (Mammotome; Ethicon EndoSurgery Inc., Cincin-
nati, OH) for the percutaneous removal of fibroadenomas and
small malignancies [8e15]. In these studies, the procedure
was well tolerated and successful in 38%e85% of patients
with a benign mass and was less effective in patients withsmall cancers, with success being defined as no imaging
evidence of residual mass at the time of excision and/or on
follow-up imaging. The variable success rate likely reflects
differences in devices, patient selection, and operator expe-
rience. To date, there are no published reports of using newer
vacuum-assisted devices for this purpose. Such devices
include the Bard Vacora (Bard Peripheral Vascular Inc.,
Phoenix, AZ), EnCor device (SenoRx, Aliso Viejo, CA), and
automated tissue extraction and collection device (ATEC;
Suros Surgical Systems, Hologic, Bedford, MA). We
describe our clinical experience with the ATEC and aim to
establish its safety, efficacy, and patient acceptance for
percutaneous excision of benign breast masses.
Subjects and Methods
Forty patients (39 women, 1 man; age range 17e79 years,
mean 38.2 years) with 42 documented benign or probably
benign breast masses presented to our institution between
May 2003 and March 2005 and prospectively opted to
undergo percutaneous excision rather than surgery for
treatment of their lesion by using the ATEC device. Because
the device was used clinically in patients for a diagnosis of
breast disease, our institution’s human studies subcommittee
determined that approval of this protocol by the institutional
review board was unnecessary. Recruitment into this clinical
study entailed an extended conversation between the breast
imager and prospective patient regarding the management
options of close interval follow-up, percutaneous core needle
biopsy, conventional surgery, and percutaneous excision for
their particular imaging finding. Realistically, because
a majority of the patients had an enlarging mass on imaging,
imaging follow-up did not represent a reasonable option, and
some interventional procedure was preferred by both the
patient and the provider. However, because the radiologist
explained the pros and cons of each procedure, in addition to
the usual complications of bleeding and infection with any
biopsy, the patients were informed of the possibility of
incomplete removal that might necessitate a second proce-
dure in the future if they opted for percutaneous excision.
The potential benefits of percutaneous excision instead of
surgery were improved cosmesis and less required pre-
procedure patient preparation. The potential benefits of
surgery were guaranteed removal, but this would require
general anesthesia, potentially suboptimal cosmesis, and
additional preprocedural preparation. At our institution, all of
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anesthesia, although this varies among institutions across the
world, and some patients still prefer general anesthesia over
local anesthesia for breast surgery. Therefore, it is unclear
whether the use of general anesthesia for breast surgery at
our institution could have biased any of our patients to
choose this percutaneous approach rather than surgery for
managing their benign breast mass.
Acceptable indications for this study included patients
with an enlarging or tender known fibroadenoma as proven
on prior biopsy (n ¼ 8), an enlarging or tender probably
benign finding (n ¼ 17), or a probably benign mass for which
the patient desired excision (n ¼ 17). Patients who desired
excision but who did not choose to undergo conventional
surgery tended to fall into 2 categories: those with a strong
positive family history (n ¼ 4) or those with a personal
history of breast cancer (n ¼ 13). Three of the 17 patients
with enlarging probably benign findings wanted the breast
abnormality excised but were considered poor surgical
candidates, which made the risks of conventional surgery
with general anesthesia far outweigh the likelihood that the
breast finding would result in eventual patient mortality. Five
women had a history of at least 1 or more fibroadenomas that
had been treated with surgical excision.
Imaging modalities used to suggest the diagnosis of
a benign breast mass included mammography and ultrasound
for patients older than 30 years and ultrasound alone for
patients younger than 30 years. Mammography was per-
formed by using dedicated mammography units (Instru-
mentarium Performa and Diamond; General Electric,
Milwaukee, WI). Breast ultrasound was performed by using
an HDI5000 unit, with either a broadband 12-5 MHz linear
transducer (Philips Medical Systems, Bothell, WA). Lesion
size was measured in 3 dimensions in radial and antiradial
planes, and lesion volume was calculated based on the
standard formula for an ellipsoid (L  H W  0.52). A 13-
to 14-gauge coaxial spring-loaded system (Biopty; Bard
Urological, Covington, GA) was used for patients who
underwent a diagnostic core biopsy before percutaneous
excision.
All procedures were performed with the patients in
a supine or supine oblique position, in an ambulatory setting
at our breast-imaging centre, under local anesthesia and
sterile conditions. After explaining procedural details to the
patient and obtaining written informed consent, percutaneous
removal was performed by using either a 9-gauge (n ¼ 13) or
12-gauge (n ¼ 29) ATEC device by 1 of 2 radiologists
experienced in interventional breast procedures. It is well
established that the ATEC device can obtain up to 16
samples/min, with each sample having a volume of
approximately 125e150 mL. With the patient under local
anesthesia (1% Xylocaine), a small incision was made with
a #11 scalpel. We no longer routinely administer Xylocaine
with epinephrine for any percutaneous biopsy at our insti-
tution, because, in our experience, we noticed no difference
in bleeding complications. The probe was then placed
posterior and contiguous to the mass under sonographicguidance (Figure 1, A and B). For larger lesions, the probe
was placed centrally within the lesion. During the procedure,
continuous ultrasound imaging was performed to allow
rotation of the cutting surface of the probe towards areas of
residual mass (Figure 1C). The procedure continued until
there was no visible sonographic evidence of the lesion
(Figure 1D). In 32 patients, after evacuation of any hema-
toma, a marking clip (Ethicon EndoSurgery and SenoRx
[Aliso Viejo, CA]) was deployed through the probe. For the
other 8 patients, a marking clip was not used because the
patients had previously undergone a biopsy that confirmed
a benign diagnosis. At the conclusion of the procedure, the
probe was removed, and compression was applied for
a minimum of 10 minutes to assure hemostasis. Steri-Strips
were applied to close the incision, and the patient’s chest
was then wrapped with an elastic band to apply continuous
pressure for 2e4 hours. A small ice pack was placed in the
elastic dressing, and the patients were instructed to apply ice
to minimize postprocedure discomfort. Each procedure
averaged 20e40 minutes, depending on lesion size.
Data recorded included technical success, complications,
and patient experience (with respect to pain, bleeding, and
bruising) during and 48 hours after biopsy. Pain and bleeding
were reported on a scale of 0e10, and bruising was reported on
a scale of 0e5. Scores were classified into 4 categories (none,
minimal, moderate, and severe) based on the following
criteria: no pain, bruising, or bleeding¼ score of 0; minimal¼
score of 1e3 for pain and/or bleeding, a score of 1e2 for
bruising; moderate ¼ score of 4e7 for pain and/or bleeding,
score of 3 for bruising; severe¼ score of 8e10 for pain and/or
bleeding, score of 4e5 for bruising.
All lesions were sent to pathology for histologic exami-
nation. Surgical excision was recommended when the
pathology revealed atypia or malignancy (n ¼ 3). Follow-up
imaging (ultrasound, mammography, or both) was recom-
mended at 6 months for the remaining lesions (n ¼ 39). For
26 lesions, follow-up imaging was available, and the
procedure was classified as a complete success when there
was no evidence of a residual mass on the follow-up
imaging. For 10 lesions with no follow-up imaging, clin-
ical follow-up was obtained. Three lesions were lost to
follow-up.
Results
Forty-two ultrasound-guided breast biopsies were per-
formed in 40 patients. Thirty-eight patients had 1 lesion
(right breast, n ¼ 22; left breast, n ¼ 16), and 2 patients had 2
lesions (1 patient with 2 right breast lesions and 1 patient
with 2 left breast lesions). Of the 42 lesions, 26 were
palpable (62%). Maximal lesion diameters ranged from 0.6e
4.0 cm (mean 1.6 cm) with lesion volumes between 0.05 and
11.2 mL (mean [SD] 1.4  2.1 mL, median 7 mL). The
lesions were classified into 3 groups based on pre-excisional
sonographic imaging: circumscribed hypoechoic (n ¼ 28),
circumscribed isoechoic (n ¼ 3), and lobulated hypoechoic
(n ¼ 8). Three lesions had both cystic and solid components.
Figure 1. (A) A 27-year-old woman with a history of 2 surgically excised fibroadenomas now with a tender, lobulated, 17-mm mass in right breast at 11
o’clock. A core biopsy 6 months earlier confirmed fibroadenoma. Increasing symptoms led the patient to pursue excision, although she was very reluctant to
undergo surgery. (B) Prebiopsy placement of 9-gauge ATEC device, showing the probe posterior and contiguous to the lesion. (C) Representative image during
the process of lesion removal, showing the probe relative to the residual mass, thereby permitting rotation of the probe towards the residual mass, which
resulted in complete excision. (D) Postbiopsy image, showing no residual mass, consistent with complete removal on the day of the procedure. On a 6-month
follow-up ultrasound, this patient’s fibroadenoma had not recurred.
Table 1
Patient reported complications (reported in percentages)
None Minimal Moderate Severe
Pain 47.5 (n ¼ 19) 45 (n ¼ 18) 5 (n ¼ 2) 2.5 (n ¼ 1)
Bruising 65 (n ¼ 26) 27.5 (n ¼ 11) 5 (n ¼ 2) 2.5 (n ¼ 1)
Bleeding 77.5 (n ¼ 31) 20 (n ¼ 8) 2.5 (n ¼ 1) 0
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completely excised in all cases because no visible residual
mass was seen on postprocedural ultrasound. For 3 of the
early cases, a second ATEC device was needed to complete
the excision when the device became progressively less
efficient in excising the tissue. Since that time, the manu-
facturer has made improvements to the cutting surface, and
we did not encounter this as a problem in any of our later
cases. The tissue filter had to be replaced during the proce-
dure in 5 cases when it completely filled with tissue and
blood products. In these 8 cases, the lesions all had maximal
dimension 2 cm and volume 2.3 mL.
The ATEC procedure was well tolerated by virtually all
patients. Patients reported no pain or discomfort during the
procedure, and there were no immediate major complica-
tions. Only 2 patients (5%) experienced moderate bleeding at
the time of excision. Forty-eight hours after the procedure,
the patients reported minimal or no complications (Table 1).
Six patients had a moderate hematoma at the biopsy site, 3
had blisters from the Steri-Strips (3M Health Care, St Paul,
MN), and 6 had mild pain or soreness. Regardless of these
minor complaints, all the patients still would have chosen to
undergo the procedure again if faced with the same decision.Both the 9- and 12-gauge probes were equally effective in
excising the target lesion on the day of the biopsy. We used
the 12-gauge needle exclusively for smaller masses that
ranged from 0.6e1.2 cm, with lesion volumes from 0.05e0.5
mL. The 9-gauge needle was used for lesions that varied
from 2.4e4.0 cm, with lesion volumes between 2.0e11.2
mL. Those lesions that ranged from 1.3e2.2 cm in maximum
dimension with volumes from 0.6e1.2 mL were excised by
using either probe. The t tests demonstrated a significant
difference in both maximum lesion dimension (t [40] ¼ 5.51,
P < .001) and lesion volume (t [40] ¼ 5.51, P < .001)
between the 9-gauge and 12-gauge needle probes. There
were no significant differences in patient-reported compli-
cations of pain, bruising, and bleeding between the 2 sizes. In
reality, however, the larger probe could be used to excise
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using a slightly larger incision but necessitating fewer cores.
Pathology of the 42 excised tissue samples showed 41
benign lesions (98%) and 1 malignancy (2%) (Table 2). The
majority of excised lesions were classified as fibroadenomas
or fibrocystic change. Lesion pathology was concordant with
imaging findings in 39 of the 42 lesions (93%). Three lesions
required surgical intervention because of atypia or malig-
nancy. For 2 of these 3 cases (5%), atypical ductal hyper-
plasia was associated with a fibroadenoma and an intraductal
papilloma, respectively, and surgical excision of the biopsy
bed was performed. In both of these cases, no malignancy
was found at surgery and no residual mass was discovered. In
the other case, papillary carcinoma was diagnosed upon
percutaneous excision, despite prior core biopsy, which
revealed a benign papillary lesion. The patient subsequently
underwent lumpectomy, and final pathology revealed multi-
focal papillary carcinoma, with adjacent areas of invasive
lobular carcinoma and ductal carcinoma in situ.
Of the remaining 39 of 42 lesions (93%), 26 (67%) had
follow-up imaging (average 10.2 months, range 6e20
months), and 24 of the 26 lesions (92%) showed no residual
mass on follow-up ultrasound and/or mammography. For 9
patients with 10 palpable lesions, only clinical follow-up was
available; however, there was no residual palpable mass on
physical examination (average 21.5 months, range 11e29
months), and hence, the patient’s symptoms had been
successfully treated with this approach. Two patients with 3
benign lesions (7%) were lost to follow-up.
In summary, for the 39 lesions excised by using this
ultrasound-guided percutaneous method for which clinical,
imaging, and/or surgical follow-up was available, percuta-
neous excision either relieved the patient’s symptoms or
completely removed the mass in 36 cases (92%).
Discussion
Fibroadenomas, fibrocystic change, and other benign
breast disease are commonly encountered in clinical practice
[3]. In most cases of a probably benign palpable abnormality,
short-interval clinical or imaging follow-up and/or percuta-
neous core needle biopsy to confirm the benign etiology
represent reasonable options for management. However, it is
well known that up to 32% of fibroadenomas will enlargeTable 2
Pathology results for 42 lesions after percutaneous excision
Pathology % cases
Fibroadenoma 74 (n ¼ 31)
Associated atypia (n ¼ 1)
Fibrocystic change 10 (n ¼ 4)
Intraductal papilloma 7 (n ¼ 3)
Associated atypia (n ¼ 1)
Intramammary lymph node 2 (n ¼ 1)
Papillary carcinoma 2 (n ¼ 1)
Othera 5 (n ¼ 2)
aIncludes lipoma and a ruptured duct with fat necrosis.over time [18e20]. When this occurs, despite a prior benign
core biopsy, the consensus is to recommend surgical exci-
sion, although it is unusual that the eventual pathology
reveals anything but a fibroadenoma. In addition, there are
some women who prefer removal of their benign mass to
alleviate their physical discomfort and/or emotional distress.
Open surgical biopsy represents 1 option for these women
who desire removal of a known benign or probably benign
mass. Since the introduction of core needle biopsy for
diagnosis, vacuum-assisted devices have been used in several
studies, not only for diagnosis but also for definitive treat-
ment [4,21,22]. By using the 11-gauge Mammotome device
under sonographic guidance, Sperber et al [9] successfully
removed 57% of 56 fibroadenomas. In a similar study, Fine
et al [10] completely excised 99% of palpable benign lesions
by using an 8-gauge handheld Mammotome probe and 96%
of such lesions with the 11-gauge probe under ultrasound
guidance on the day of biopsy. On 6-month follow-up, 98%
of the lesions remained nonpalpable, with no sonographic
evidence of the original mass in 73% of patients. March et al
[8] also used the 11-gauge Mammotome device to percuta-
neously excise 26 benign and 8 malignant palpable lesions
under sonographic guidance. However, whereas all target
lesions were completely removed on the day of the biopsy,
incomplete excision was found in 6 of 10 patients with
cancerous lesions, and a residual mass was found in 38%,
with a benign mass on 6-month follow-up imaging. More
recently, Grady et al [23] reported an overall recurrence rate
of 15% for 82 percutaneously excised consecutive fibroa-
denomas, seen only in lesions more than 2 cm in size as
documented on follow-up imaging.
To our knowledge, this is the first report that details the
use of the ATEC device for the percutaneous removal of
benign breast masses. On the day of biopsy, all of the lesions
appeared to be completely removed. However, 1 patient
subsequently underwent surgery, which revealed a residual
papillary carcinoma, at which time the surgical margins
could be assessed because this is not possible when using this
vacuum-assisted percutaneous approach. Two patients had
a residual mass on follow-up imaging at 6 months, although
they remained asymptomatic. More importantly, the proce-
dure appeared to be effective for 26 of 29 lesions (90%) for
which follow-up imaging or surgery revealed no residual
mass. In addition, for the 9 patients with 10 palpable lesions
with only clinical follow-up, there was no residual palpable
mass on follow-up physical examination by their provider.
The high success rate accomplished in this study when
using the ATEC device rather than the Mammotome likely is
multifactorial. Unlike earlier devices, the ATEC device is
a closed system that operates continuously, removing up to
16 samples per minute. This allowed the radiologist to focus
solely on positioning the probe adjacent to the residual
portion of the lesion. The gauge of the device also could be
tailored to better match lesion volume, because the ATEC is
available in 9-gauge and 12-gauge sizes. Lesions up to 4 cm
in maximal dimension and 11.2 mL in volume were
completely excised on the day of biopsy. Although both
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recommend using the 12-gauge needle for lesions 1.2 cm
in maximal dimension and the 9-gauge probe for lesions
2.4 cm to minimize any scarring from the small scalpel
incision. However, either probe should be effective for the
removal of a benign mass. Practically, the 9-gauge probe
requires a slightly larger incision than the 12-gauge device,
but its main advantage would be the need to acquire fewer
cores to successfully remove a mass. Finally, the criteria for
enrollment into this study were fairly restrictive, such that
only patients with known benign or probably benign masses
4 cm or smaller in maximal dimension could participate.
Similar to other reports of using this technology for
percutaneous excision [8,10,13e16], this minimally invasive
procedure was well tolerated and accepted by our patients,
with no reported major complications. All the patients who
participated in this protocol strongly expressed their prefer-
ence for this procedure over open surgical biopsy. It appeared
that this minimally invasive approach is safe and efficacious
but with decreased pain, trauma, and scarring, and less
postprocedure recovery compared with traditional surgery.
Furthermore, in a similar study of using a similar device
(Mammotome) for percutaneous excision, Alonso-Bartolome
et al [24] showed that this approach can be cost effective,
being 82% less expensive than surgery and 71% less time for
the patient.
Although percutaneous excision by using the ATEC
vacuum-assisted device appeared to be efficacious, 1 limi-
tation of this study was the relatively small sample size of 42
lesions. Although the average follow-up duration in this
study was 13 months (range 6e29 months), 10 lesions had
only clinical follow-up, and 3 patients were lost to follow-up.
Larger trials with longer follow-up intervals that compare
this specific technique with standard surgical excision seem
warranted, because it appears that this technique is a viable
option instead of surgical excision for selected patients.
Another limitation may be related to the fact that breast
surgery at our institution is only performed with the patient
under general anesthesia, and we did not ask patients how
this might have influenced their decision to opt for percuta-
neous excision. Finally, because many of our patients had
a strong family or personal history of breast cancer, the
cohort of participants may not be representative of the
general population, because these women tend to opt for
biopsy more frequently than average-risk women.
It is well known that vacuum-assisted core biopsy has
lower false-negative rates than fine needle aspiration or
conventional spring-loaded core biopsy, likely because of the
larger volume of sampled tissue [12,21,25]. However, as in
our study in which 2 women had incidental atypical ductal
hyperplasia adjacent to the benign mass, it was clear that not
all women who undergo this procedure will be able to avoid
open surgical biopsy. Therefore, although we did not
routinely place a clip to mark the biopsy bed for all of our
cases in this study, we would recommend that a clip be
deployed in any patient undergoing percutaneous excision
for a benign or probably benign mass, despite a previous corebiopsy that confirmed a benign diagnosis, because we did
encounter 1 patient early on in the study that, upon excision,
revealed papillary carcinoma rather than the previously core
biopsy-proven intraductal papilloma. The routine practice of
clip placement after percutaneous excision will ensure
accurate localization of the biopsy bed before surgical
excision for the minority of patients with unsuspected atypia
or even malignancy on final pathologic analysis of the
percutaneously excised tissue.
Conclusion
In summary, our study showed that ultrasound-guided
percutaneous excision of benign breast masses when using
the vacuum-assisted ATEC device was a safe, effective, and
well-tolerated minimally invasive procedure for the diag-
nosis and definitive treatment of documented benign and
probably benign breast masses. It appeared to be a feasible
option and may serve as a suitable alternative to surgical
excision for those patients who (1) would prefer removal yet
do not want to undergo surgical excision for fear of poor
cosmetic outcome; (2) have a history of multiple surgeries
and face another benign mass; or (3) have a probable benign
mass but are poor surgical candidates. Further study in
a larger patient population with benign breast lesions and
long-term follow-up to assess for recurrence seems
warranted.
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